Randomized, Double-blind, Multi-center Study Comparing MCC to BCG as First Line Immunotherapy in Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Recurrence or Progression.

Trial Profile

Randomized, Double-blind, Multi-center Study Comparing MCC to BCG as First Line Immunotherapy in Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Recurrence or Progression.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 27 Oct 2014

At a glance

  • Drugs Mycobacterium cell wall DNA complex (Primary) ; BCG
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Sponsors Endo Pharmaceuticals; Telesta Therapeutics
  • Most Recent Events

    • 28 Jan 2011 This trial was withdrawn prior to enrollment according to the ClinicalTrials.gov record.
    • 28 Jan 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top